- FDA, EU MDR, and ISO 11607 create a three-layered compliance requirement where ISO 11607 serves as the common technical foundation, but FDA 21 CFR Part 820 adds process validation demands and EU MDR 2017/745 adds chemical safety and sustainability requirements that ISO 11607 alone does not satisfy.
- The most common 510(k) delay cause related to packaging is insufficient sterile barrier validation data — specifically, seal strength testing that only sampled 3 points rather than continuous peel testing across the full seal perimeter.
- EU MDR Article 10(9) now requires manufacturers to document and reduce risks from hazardous substances in packaging materials — a requirement that directly impacts film selection and favors single-material or biodegradable sterile barrier systems like coated cellulose.
Why Medical Packaging Compliance Is a Multi-Regulator Challenge (Not a One-Standard Problem)
I have lost count of how many medical device entrepreneurs have told me, "Our packaging film is ISO 11607 compliant, so we are ready for both FDA and CE marking." This statement reveals a fundamental misunderstanding that I want to address immediately: ISO 11607 compliance is necessary but not sufficient for either FDA clearance or EU MDR CE marking — it satisfies the technical validation requirements that both regulators reference, but neither regulator considers ISO 11607 compliance alone as evidence that your sterile barrier system meets their respective legal requirements.
The compliance landscape for medical packaging films in 2026 is a three-jurisdiction challenge that requires medical device manufacturers to satisfy: (1) FDA 21 CFR Part 820 Quality System Regulation for devices sold in the United States, (2) EU Medical Device Regulation 2017/745 for devices sold in the European Union, and (3) ISO 11607-1:2019 and ISO 11607-2:2019 as the harmonized technical standard that both regulators use as the benchmark for sterile barrier system validation. Because FDA's Quality System Regulation mandates design controls and process validation that go beyond ISO 11607's scope, and EU MDR adds chemical safety requirements under Annex I General Safety and Performance Requirements (GSPR) that neither FDA nor ISO 11607 addresses, a packaging film validated solely to ISO 11607 test methods can still fail FDA premarket notification or EU MDR technical documentation review.
At XIADE, we maintain a compliance tracking matrix that maps each requirement from FDA 21 CFR Part 820 and EU MDR 2017/745 against the corresponding test methods from ISO 11607. The matrix contains 47 distinct requirements — of which ISO 11607 directly addresses 28 (60%), FDA Part 820 adds 11 additional requirements, and EU MDR adds 8 requirements that neither FDA nor ISO 11607 covers. This article walks through each of these three regulatory frameworks from the perspective of a packaging film supplier who has supported 23 medical device 510(k) submissions and 8 CE marking technical documentation packages, and it identifies the specific compliance gaps that we most frequently see in our clients' sterile barrier validation dossiers.
FDA 21 CFR Part 820 — What Medical Device Companies Need from Packaging Films
The FDA's Quality System Regulation, codified in 21 CFR Part 820, does not contain a dedicated "packaging" section. Instead, sterile barrier requirements are distributed across three subsections: §820.30 Design Controls, §820.70 Production and Process Controls, and §820.130 Device Packaging. The FDA's approach to packaging validation is process-centric rather than material-centric — it requires documented evidence that your packaging process (including film selection, sealing parameters, and sterilization cycle) consistently produces a sterile barrier that meets design specifications, rather than requiring the film material itself to carry a specific certification.
The practical implication for medical device manufacturers is that purchasing an ISO 11607-compliant packaging film from XIADE or any other supplier is the beginning of your FDA compliance work, not the end. Under §820.30 Design Controls, you must establish design input requirements for your sterile barrier system that include: (1) the sterilization method and cycle parameters, (2) the intended shelf life, (3) the distribution and storage environment (temperature range, humidity range, atmospheric pressure range for air-freight), and (4) the seal integrity acceptance criteria. Under §820.70, you must validate every sealing process parameter combination with installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ) that the FDA considers equivalent to ISO 11607-2 process validation — but the FDA reviewers I have interacted with during 510(k) reviews consistently ask for one additional piece of data that ISO 11607-2 does not require: seal strength data across the full temperature tolerance band of your sealing equipment, not just at the nominal setpoint.
In 2024, the FDA issued a Quality System Regulation amendment that aligns Part 820 more closely with ISO 13485:2016, which I view as a positive development because the harmonization of FDA QSR with ISO 13485 reduces the documentation burden on manufacturers serving both US and EU markets — a single quality management system can now satisfy both regulators, provided the EU MDR-specific chemical safety and clinical evaluation documentation requirements are separately addressed. The key packaging-related change in the harmonized QSR is the explicit requirement for risk management documentation per ISO 14971 that specifically addresses sterile barrier failure modes, which was previously implied but not explicitly stated in Part 820.
EU MDR 2017/745 — The Sterile Barrier System Requirements That Are Catching Companies Off Guard
If FDA Part 820 is process-centric, EU MDR 2017/745 is risk-centric — and it imposes sterile barrier system requirements that go well beyond what ISO 11607 validation alone demonstrates. EU MDR Annex I, General Safety and Performance Requirements (GSPR) Section 11.4 requires that devices delivered in a sterile state must be "packaged in a system that maintains sterility under the storage, transport, and handling conditions specified by the manufacturer," and Section 10.4 requires that packaging materials must not "release substances that could impair the safety or performance of the device" — a chemical safety requirement that has no direct parallel in FDA regulation or ISO 11607.
I have seen three CE marking technical documentation reviews rejected specifically because of packaging-related GSPR nonconformities. The first: a manufacturer who had validated their PE/EVOH/PE pouch to ISO 11607 microbial barrier requirements but had not provided extractables and leachables testing data per ISO 10993-18 to demonstrate that the EVOH layer's processing additives did not migrate into the device during EO sterilization and 3-year shelf life. The second: a spinal implant manufacturer who used a foil composite pouch that passed all ISO 11607 performance tests but whose aluminum layer was flagged by the Notified Body reviewer under GSPR 10.4 because the manufacturer had not documented the aluminum's recycling pathway or justified why a non-recyclable multi-material laminate was necessary for device safety. The third — and this one still frustrates me — was rejected because the manufacturer's packaging film supplier (not XIADE) could not provide a Declaration of Conformity to EU food contact material Regulation (EC) 1935/2004, which the Notified Body reviewer considered relevant under the precautionary principle even though medical devices are not directly regulated under food contact legislation.
EU MDR Article 10(9) requires manufacturers to establish, document, implement, and maintain a system for risk management that specifically addresses risks associated with hazardous substances in materials — and by 2028, the Packaging and Packaging Waste Directive (PPWD) 2018/851 amendment is expected to add specific recyclability or biodegradability requirements for medical packaging sold in the EU market. This regulatory vector is the single strongest structural driver toward cellulose-based and other biodegradable sterile barrier systems that I have observed in my 17-year career, and I expect it to fundamentally reshape the medical packaging film market between 2026 and 2030.
ISO 11607 Deep Dive — The Technical Standard That Satisfies Both FDA and EU MDR
ISO 11607-1:2019 establishes the performance requirements for materials, preformed sterile barrier systems, and packaging systems for terminally sterilized medical devices. It is the technical bridge between the FDA's process expectations and EU MDR's risk management framework. ISO 11607-1 requires five categories of evidence for sterile barrier system validation: (1) microbial barrier properties — minimum 6-log reduction value per ASTM F1608 for porous materials or per ASTM F2638 for non-porous, (2) seal strength ≥ 1.5 N/15mm per ASTM F88 with visual inspection for channel defects per ASTM F1886, (3) material compatibility with the sterilization process — no degradation of barrier or strength properties after exposure to the maximum sterilization dose, (4) biocompatibility per ISO 10993-1 appropriate to the device's patient contact classification, and (5) stability — real-time and accelerated aging data demonstrating maintenance of sterile barrier properties through the claimed shelf life.
What ISO 11607 does NOT require — and this is the gap that catches companies during regulatory review — is evidence of chemical safety (EU MDR GSPR 10.4), environmental impact assessment (emerging EU requirements under PPWD), or supply chain traceability documentation (increasingly demanded by hospital GPO contracts). I advise every medical device client at XIADE to treat ISO 11607 compliance as the foundation, FDA Part 820 process validation as the walls, and EU MDR GSPR documentation as the roof — you need all three, and each addresses a different aspect of sterile barrier system compliance that the others do not cover.
How to Build a Compliance Matrix: Matching Your Target Markets to Required Tests
The following compliance matrix summarizes the 12 most critical packaging-related requirements across FDA, EU MDR, and ISO 11607, with the specific test methods and acceptance criteria that I have seen reviewers accept across 31 regulatory submissions over the past decade.
| Requirement | ISO 11607 | FDA Part 820 | EU MDR 2017/745 | Test Method |
|---|---|---|---|---|
| Microbial Barrier | Required (LRV ≥ 6.0) | Required via Design Control | Required via GSPR 11.4 | ASTM F1608 / F2638 |
| Seal Strength | ≥ 1.5 N/15mm | Full tolerance band data | ≥ 1.5 N/15mm | ASTM F88 + F1886 |
| Sterilization Compatibility | Required | Required via Process Control | Required | Per sterilization method |
| Biocompatibility | Per ISO 10993-1 | Per device classification | Per GSPR 10.2 | ISO 10993 series |
| Stability / Shelf Life | Real-time + accelerated | Real-time + accelerated | Real-time + accelerated | ASTM F1980 |
| Chemical Safety | Not required | Not directly required | Required (GSPR 10.4) | ISO 10993-18 |
| Extractables & Leachables | Not required | Not required | Required (GSPR 10.4) | ISO 10993-18 |
| Environmental Impact | Not required | Not required | Emerging (PPWD) | LCA per ISO 14040 |
| Process Validation (IQ/OQ/PQ) | Required (Part 2) | Required (§820.70) | Required (GSPR 11.4) | Per equipment manufacturer |
| Risk Management | Referenced | Required (QSR Amend.) | Required (Annex I) | ISO 14971 |
| Supplier Qualification | Not required | Required (§820.50) | Required (Article 10) | Per QMS procedure |
| Post-Market Surveillance | Not required | Required (MDR reports) | Required (Vigilance) | Per QMS procedure |
I recommend that every medical device manufacturer build a custom version of this matrix for their specific device classification, sterilization method, and target markets. At XIADE, we provide our medical packaging film clients with a compliance data package that includes the specific test reports and certificates they need for each cell of this matrix — because I have learned that packaging film suppliers who simply ship a roll of film and a certificate of analysis are not actually helping their clients achieve regulatory clearance; they are outsourcing the most difficult part of the compliance work to people who are not materials scientists and may not know which test to request.
Common Compliance Pitfalls That Lead to 510(k) Delays or CE Mark Refusals
Over 17 years of supporting regulatory submissions, I have catalogued the ten most frequent packaging-related compliance failures. Here are the top four, because they account for 78% of all sterile barrier system rejections I have seen:
Pitfall 1: Three-point seal strength testing instead of full-perimeter continuous peel. ASTM F88 permits three-point sampling with an average reported as the seal strength — and FDA and EU MDR reviewers both routinely reject this approach for sterile barrier validation because a single cold spot along an 800mm seal bar can produce localized seal strength below 1.0 N/15mm while the three-point average reports 2.4 N/15mm. Every sterile barrier validation I have successfully defended required continuous peel testing at 10mm intervals along the entire seal perimeter — not because the standard explicitly demands it, but because reviewers have learned that three-point sampling systematically masks seal channel defects.
Pitfall 2: Validating only at nominal seal parameters without the tolerance band. I have seen a 510(k) submission delayed by 11 months because the manufacturer validated their foil pouch sealing process at 155°C ± 0°C, but their production sealing equipment had a documented temperature variation of ±8°C — and the reviewer correctly noted that seal strength data at 155°C provides no evidence of sterile barrier integrity at 147°C or 163°C. Seal validation must demonstrate acceptable seal strength, dye penetration, and burst test results at the full lower and upper bounds of your equipment's documented parameter tolerance — not just at the nominal setpoint.
Pitfall 3: Missing extractables and leachables data for EU MDR submissions. I mentioned this earlier but it bears repeating: any multi-layer packaging film that includes adhesives, coatings, or printing inks will require extractables and leachables testing per ISO 10993-18 for EU MDR compliance, and this testing typically takes 8–12 weeks and costs $18,000–$35,000. Budget for it. Schedule it early. XIADE's cellulose-based medical packaging films use a single-material construction with water-based coatings, which significantly simplifies the extractables and leachables documentation because the number of potential migrant substances is inherently limited to the plasticizer, coating, and cellulose substrate — typically ≤ 5 potential migrants versus ≥ 40 for a multi-layer synthetic laminate.
Pitfall 4: Shelf-life validation that stops at accelerated aging without real-time confirmation. Accelerated aging per ASTM F1980 at 55°C for 60 days can provide a reasonable prediction of 2-year ambient stability, but reviewers increasingly demand that the device manufacturer commit to providing real-time aging data as it becomes available — and if the real-time data at 18 months shows seal strength degradation that the accelerated aging did not predict, you will be expected to file a field safety corrective action. I recommend initiating real-time aging samples on the same day you initiate accelerated aging, because the 2-year clock on real-time data starts the moment your device is packaged and sterilized.
For medical device companies navigating these multi-jurisdiction compliance challenges, I welcome technical inquiries through the XIADE contact page. We maintain a library of sterile barrier validation templates that our clients have used to structure their FDA 510(k) and EU MDR technical documentation submissions, and I am always willing to discuss how our cellulose-based medical packaging films and coated cellulose variants map onto your specific compliance matrix requirements.
Frequently Asked Questions
- Q1: What are the key differences between FDA and EU MDR requirements for medical packaging films?
- The fundamental difference is philosophical: FDA Part 820 is process-oriented, requiring documented evidence that your packaging process consistently produces a sterile barrier meeting design specifications. EU MDR is risk-oriented, requiring documented evidence that you have identified, assessed, and mitigated all risks associated with the packaging material — including chemical risks from material migrants, environmental risks from disposal, and clinical risks from sterile barrier failure. In practical terms, this means an FDA submission can be satisfied with ISO 11607 microbial barrier and seal strength data plus process validation (IQ/OQ/PQ) documentation. An EU MDR submission requires all of that plus: extractables and leachables testing per ISO 10993-18, a documented justification that packaging material chemical migrants do not impair device safety (GSPR 10.4), and for devices entering the EU market after 2028, documentation addressing the packaging material's end-of-life environmental pathway under PPWD 2018/851. The documentation burden for EU MDR is approximately 40%–60% greater than for FDA 510(k) for the same sterile barrier system, and this difference is the primary reason I recommend that manufacturers target EU MDR compliance first — satisfying EU MDR essentially covers FDA requirements automatically in the packaging domain, but the reverse is not true.
- Q2: What testing is required for ISO 11607 compliance?
- ISO 11607-1:2019 requires five categories of testing, each of which must be performed on samples that have undergone the full sterilization process and accelerated aging equivalent to the claimed shelf life: (1) Microbial barrier testing — ASTM F1608 (porous materials) or ASTM F2638 (non-porous materials) with a minimum log reduction value of 6.0, demonstrating that the sterile barrier system prevents the ingress of challenge microorganisms (typically Bacillus atrophaeus spores, 0.5–2.0 μm) under a defined pressure differential. (2) Seal strength testing — ASTM F88 peel testing with minimum seal strength of 1.5 N/15mm, plus ASTM F1886 visual inspection for channel defects with zero defects permitted. (3) Material compatibility — demonstration that the packaging material does not degrade under the intended sterilization process (EO at maximum concentration and temperature, gamma at maximum dose, or steam at maximum cycle temperature and duration). (4) Biocompatibility — ISO 10993-1 evaluation appropriate to the device classification, typically cytotoxicity (ISO 10993-5), sensitization (ISO 10993-10), and irritation (ISO 10993-10 or -23) for external-communicating devices. (5) Stability — real-time aging at 23°C ± 2°C and 50% ± 10% RH for the claimed shelf life, plus accelerated aging per ASTM F1980 at elevated temperature (typically 55°C) calculated using a Q10 factor of 2.0. The accelerated aging data may be submitted for initial regulatory clearance, but real-time data must be committed to and provided as it becomes available.
- Q3: How does EU MDR Article 7 affect medical device packaging validation requirements?
- EU MDR Article 7 addresses the use of hazardous substances in medical devices and their packaging. Specifically, Article 7(1) requires that devices "shall be designed and manufactured in such a way as to ensure that the risks posed by the leaching or migration of hazardous substances are reduced as far as possible," and Article 7(4) extends this requirement to substances that are carcinogenic, mutagenic, or toxic to reproduction (CMR) and endocrine-disrupting chemicals. For packaging films, this means: (1) any phthalate-based plasticizers in the film formulation must be justified with a risk-benefit analysis demonstrating that no technically feasible alternative exists, (2) any coating or adhesive chemistry that includes substances on the Candidate List of Substances of Very High Concern (SVHC) under REACH must be disclosed and justified, and (3) the packaging supplier must provide a full material disclosure — not just a certificate of compliance — identifying all intentionally added substances at concentrations above 0.1% w/w. XIADE's cellulose-based films use glycerol and water as primary plasticizers, and our aluminized coating chemistry is free of per- and polyfluoroalkyl substances (PFAS), phthalates, and bisphenol A (BPA) — which significantly simplifies Article 7 compliance documentation compared to synthetic multi-layer laminates.
- Q4: What is the shelf life requirement for sterile barrier systems under ISO 11607?
- ISO 11607 does not prescribe a specific shelf life — it requires that the manufacturer establish the shelf life through stability testing and provide objective evidence that sterile barrier properties are maintained through the entire claimed period under worst-case storage and handling conditions. The shelf life must be supported by: (1) accelerated aging data per ASTM F1980, typically using a Q10 factor of 2.0 at 55°C to simulate ambient aging — for example, 60 days at 55°C simulates approximately 2 years at 23°C, and (2) real-time aging data initiated concurrently with accelerated aging, with one-year, two-year, and end-of-shelf-life time points tested for microbial barrier integrity, seal strength, and material properties. The practical shelf life for common medical packaging films under ISO 11607 validation is: Tyvek 1073B — up to 5 years with demonstrated microbial barrier maintenance; foil composite laminates — 3 to 5 years depending on seal integrity through thermal cycling; coated cellulose (XIADE aluminized) — 2 to 3 years with the key limitation being moisture absorption at >65% RH storage conditions; and coextruded PE/EVOH/PE — 3 to 5 years provided the EVOH layer is protected from humidity by adequate PE skin layers. A common mistake is claiming a 5-year shelf life based on accelerated aging data alone — I have seen Notified Body reviewers reject this and require real-time data at the 3-year time point before accepting a >3-year shelf life claim.
- Q5: Can a single packaging film pass both FDA and EU MDR requirements simultaneously?
- Yes — and this is the efficient path that I recommend to every medical device manufacturer. A sterile barrier system validated to ISO 11607-1 and ISO 11607-2 test methods, supported by full process validation documentation (IQ/OQ/PQ), extractables and leachables data per ISO 10993-18, and risk management documentation per ISO 14971, will satisfy both FDA Part 820 and EU MDR GSPR requirements for the sterile barrier system. The key to a single-validation approach is testing to the most demanding requirement from each regulator: use EU MDR GSPR 10.4 as the driver for chemical safety testing (since FDA does not directly require it), use FDA Part 820 §820.70 as the driver for full tolerance-band process validation (since EU MDR GSPR is less explicit about the tolerance band requirement), and use ISO 11607 as the common technical performance standard that both regulators accept. At XIADE, we provide our medical packaging film clients with a compliance data package structured to this "highest common denominator" approach — it costs approximately 15%–25% more in testing budget than a single-jurisdiction validation but eliminates the need to repeat validation work when entering the second market, delivering a net savings of 30%–40% compared to sequential single-jurisdiction validations.